Review




Structured Review

Biogen Inc dac hyp
Dac Hyp, supplied by Biogen Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/dac-hyp/dac+hyp/fda_document____drugsatfda_docs_slash_nda_slash_2016_slash_761029orig1s000otherr-949-5-14
Average 86 stars, based on 1 article reviews
dac hyp - by Bioz Stars, 2026-09
86/100 stars

Images

Related Articles

other:

Article Title: Efficacy and Safety of the Newer Multiple Sclerosis Drugs Approved Since 2010.
Article Snippet: Multiple sclerosis treatment faces tremendous changes as a result of the approval of new medications.. The new medications have differing safety considerations and risks after long-term treatment, which are important for treating physicians to optimize and individualize multiple sclerosis care.. Since the approval of the first multiple sclerosis capsule, fingolimod, the armamentarium of multiple sclerosis therapy has grown with the orally available medications dimethyl fumarate and teriflunomide.



Similar Products

86
Biogen Inc dac hyp
Dac Hyp, supplied by Biogen Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/dac-hyp/dac+hyp/fda_document____drugsatfda_docs_slash_nda_slash_2016_slash_761029orig1s000otherr-949-5-14
Average 86 stars, based on 1 article reviews
dac hyp - by Bioz Stars, 2026-09
86/100 stars
  Buy from Supplier

90
Biogen Inc daclizumab high-yield (dac hyp
Daclizumab High Yield (Dac Hyp, supplied by Biogen Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/dac-hyp/daclizumab+high+yield+antibody/us11986526-506-0-6
Average 90 stars, based on 1 article reviews
daclizumab high-yield (dac hyp - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

90
Biogen Inc daclizumab high-yield process (dac hyp, zinbrytatm)
Daclizumab High Yield Process (Dac Hyp, Zinbrytatm), supplied by Biogen Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/dac-hyp/daclizumab+high+yield+antibody/pm36082452-103-21-29
Average 90 stars, based on 1 article reviews
daclizumab high-yield process (dac hyp, zinbrytatm) - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

90
Biogen Inc daclizumab high-yield process dac hyp biib019
Daclizumab High Yield Process Dac Hyp Biib019, supplied by Biogen Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/dac-hyp/daclizumab+high+yield+antibody/us10646569-2527-0-6
Average 90 stars, based on 1 article reviews
daclizumab high-yield process dac hyp biib019 - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

90
Biogen Inc dac high yield (dac hyp
Selected Clinical and MRI Outcomes of <t> DAC HYP </t> Treatment in RMS Controlled Trials.
Dac High Yield (Dac Hyp, supplied by Biogen Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/dac-hyp/dac+hyp/pmc06480729-39-6-13
Average 90 stars, based on 1 article reviews
dac high yield (dac hyp - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

90
Biogen Inc dac-hyp
Selected Clinical and MRI Outcomes of <t> DAC HYP </t> Treatment in RMS Controlled Trials.
Dac Hyp, supplied by Biogen Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/dac-hyp/dac+hyp/pm29600441-355-9-5
Average 90 stars, based on 1 article reviews
dac-hyp - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

90
Biogen Inc dac hyp therapy
Selected Clinical and MRI Outcomes of <t> DAC HYP </t> Treatment in RMS Controlled Trials.
Dac Hyp Therapy, supplied by Biogen Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/dac-hyp/dac+hyp/pm27138097-8-32-52
Average 90 stars, based on 1 article reviews
dac hyp therapy - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

Image Search Results


Selected Clinical and MRI Outcomes of  DAC HYP  Treatment in RMS Controlled Trials.

Journal: Biomedicines

Article Title: Daclizumab: Mechanisms of Action, Therapeutic Efficacy, Adverse Events and Its Uncovering the Potential Role of Innate Immune System Recruitment as a Treatment Strategy for Relapsing Multiple Sclerosis

doi: 10.3390/biomedicines7010018

Figure Lengend Snippet: Selected Clinical and MRI Outcomes of DAC HYP Treatment in RMS Controlled Trials.

Article Snippet: Subcutaneous DAC, often referred to as DAC High Yield Process (DAC HYP; Zinbryta, Biogen, Cambridge MA and AbbVie, Chicago II), demonstrated efficacy in reducing both clinical and MRI measures of disease activity in patients with relapsing forms of multiple sclerosis (RMS) and was approved to treat RMS in 2016 [ , , , ].

Techniques: Selection

Adverse Event Incidence for DAC treated patients in Controlled Trials of  DAC HYP.

Journal: Biomedicines

Article Title: Daclizumab: Mechanisms of Action, Therapeutic Efficacy, Adverse Events and Its Uncovering the Potential Role of Innate Immune System Recruitment as a Treatment Strategy for Relapsing Multiple Sclerosis

doi: 10.3390/biomedicines7010018

Figure Lengend Snippet: Adverse Event Incidence for DAC treated patients in Controlled Trials of DAC HYP.

Article Snippet: Subcutaneous DAC, often referred to as DAC High Yield Process (DAC HYP; Zinbryta, Biogen, Cambridge MA and AbbVie, Chicago II), demonstrated efficacy in reducing both clinical and MRI measures of disease activity in patients with relapsing forms of multiple sclerosis (RMS) and was approved to treat RMS in 2016 [ , , , ].

Techniques: Selection, Infection

Cutaneous AE Incidence for DAC treated patients in Controlled Trials of  DAC HYP.

Journal: Biomedicines

Article Title: Daclizumab: Mechanisms of Action, Therapeutic Efficacy, Adverse Events and Its Uncovering the Potential Role of Innate Immune System Recruitment as a Treatment Strategy for Relapsing Multiple Sclerosis

doi: 10.3390/biomedicines7010018

Figure Lengend Snippet: Cutaneous AE Incidence for DAC treated patients in Controlled Trials of DAC HYP.

Article Snippet: Subcutaneous DAC, often referred to as DAC High Yield Process (DAC HYP; Zinbryta, Biogen, Cambridge MA and AbbVie, Chicago II), demonstrated efficacy in reducing both clinical and MRI measures of disease activity in patients with relapsing forms of multiple sclerosis (RMS) and was approved to treat RMS in 2016 [ , , , ].

Techniques: Selection